Sandra P D'Angelo, MD
@sandrapdangelo
Sarcoma & Merkel cell carcinoma Medical oncologist l Immunotherapy expert l Memorial Sloan Kettering Cancer Center l Tweets are my own
31-05-2015 18:57:23
510 Tweets
1,4K Followers
522 Following
The registrational enabling Spearhead-1 study shows that afami-cel, an engineered T cell targeting MAGEA4, has promising efficacy in synovial sarcoma and MRCLS paving the way for T cell therapy in solid tumors. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Sarcoma Service at Memorial Sloan Kettering
sciencedirect.com/science/articl…